What were the results of Roche's Phase II obesity drug trial for CT-388?

Roche's Phase II trial found that the experimental obesity drug CT-388 delivered a placebo-adjusted weight loss of 22.5% without reaching a plateau at 48 weeks.

How does Roche's new obesity drug CT-388 work?

The drug mimics the effects of two gut hormones, GLP-1 and GIP, which are key to regulating blood sugar and reducing appetite.

What is Roche's strategy in the obesity drug market?

Roche aims to compete in the fast-growing obesity drug market by developing multiple drug candidates, including CT-388, and challenging dominant players like Novo Nordisk and Eli Lilly.

Home / Health / Roche Obesity Drug Shows Major Weight Loss

Roche Obesity Drug Shows Major Weight Loss

27 Jan

•

Summary

Roche's experimental obesity drug CT-388 achieved 22.5% weight loss.
The drug mimics two gut hormones regulating blood sugar and appetite.
Roche aims to challenge Novo Nordisk and Eli Lilly in the obesity market.

Roche Obesity Drug Shows Major Weight Loss

Swiss pharmaceutical firm Roche has reported positive outcomes from a Phase II clinical trial for its experimental obesity drug, CT-388. This once-weekly injection demonstrated robust weight loss, achieving a placebo-adjusted reduction of 22.5% without reaching a plateau at 48 weeks. The drug effectively mimics the action of GLP-1 and GIP, two gut hormones crucial for managing blood sugar and appetite.

These favorable results, showing a well-tolerated safety profile, bolster Roche's confidence as it prepares to initiate Phase III trials this quarter. The company bolstered its obesity drug ambitions by acquiring the dual GLP-1/GIP receptor technology from Carmot Therapeutics for $2.7 billion in late 2023.

Roche is strategically positioning itself to contend in the burgeoning obesity drug market, projected by some analysts to reach $150 billion annually by the early 2030s. The company faces strong competition from established players like Novo Nordisk and Eli Lilly.